Should I Buy IMAX? IMAX 2026 Analysis

Should You Buy Imax Corp (IMAX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

37.280

1 Day change

2.39%

52 Week Range

39.980

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Buy now, but treat it as a tactical entry near support rather than a breakout chase: price is sitting close to the 35.22 pivot and above the 33.96 first support zone.
The core bullish case is strong: accelerating fundamentals (2025/Q3 growth) plus a broad wave of analyst upgrades/price-target raises into 2026.
The main offsets are (1) heavy insider selling recently and (2) options positioning skewed bearish/defensive; these make this a “buy with skepticism,” not a clean momentum buy.

Technical Analysis

Trend/ momentum: MACD histogram is positive (0.0372) and expanding, supporting a mild bullish bias.
RSI: RSI(6)=55.3 (neutral) → not overbought, not screaming “buy,” but leaves room for upside.
Moving averages: converging MAs suggest consolidation/indecision rather than a strong trend.
Key levels: Pivot 35.22 (near-term line in the sand). Resistance: 36.48 then 37.25. Support: 33.96 then 33.19.
Pattern-based odds: modeled next-week bias positive (+3.28%), but next-month slightly negative (-0.91%) → favors a nearer-term swing rather than a long wait.
Intellectia Proprietary Trading Signals
- AI Stock Picker: no signal on given stock today.
- SwingMax: No signal on given stock recently.

Options Data

Bearish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

Sentiment: Put-heavy open interest and volume (P/C >> 1) signals bearish positioning or substantial hedging demand.
Volatility: 30D IV 44.91 vs historical vol 28.73 (IV elevated); IV percentile 80.48 → options are pricing elevated risk into upcoming catalysts.
Activity: today’s volume is low in absolute terms (47 contracts) but vs 30D average shows a spike (4.19x), so the skew is still informative.
Takeaway: options market is not confirming a “risk-on” chase here; it’s a caution flag even if the stock is bought.

Technical Summary

Sell

Buy

Positive Catalysts

- Earnings catalyst ahead: QDEC 2025 earnings on 2026-02-18 (pre-market); continued delivery vs expectations could re-rate the stock.
- Multi-year slate/visibility narrative reinforced by multiple firms (IMAX positioned as premium, event-driven cinema + local language growth).
- Broad, recent Wall Street support: multiple Buy/Outperform ratings and targets clustered in the low-to-high $40s (notably $46–$47).

Neutral/Negative Catalysts

- Trading trends: insiders are selling (selling amount up ~585% over the last month) → negative signal on near-term confidence.
- Options positioning is heavily put-skewed (OI and volume), implying market participants are leaning defensive.
- No supportive near-term news flow in the last week to force a positive re-pricing immediately.

Financial Performance

Latest reported quarter: 2025/Q3.
Revenue: $106.654M (+16.62% YoY) → solid top-line acceleration.
Net income: $20.657M (+48.65% YoY) → strong operating leverage.
EPS: $0.37 (+42.31% YoY) → meaningful earnings growth.
Gross margin: 61.29% (up 13.29% YoY) → improving profitability profile supports the bull thesis.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: strongly positive—multiple December 2025 upgrades/target raises clustered around $42–$47.
Notable changes: JPMorgan upgraded to Overweight (PT $47 from $32); Wells Fargo raised PT to $47; Wedbush raised to $46 and kept IMAX on Best Ideas.
Wall Street “pros” view: IMAX seen as uniquely levered to premium/event cinema, expanding footprint, improving visibility through 2028, and margin expansion potential.
Wall Street “cons” (implied): execution/box-office slate dependency and timing risk around the release calendar; near-term positioning (options/insiders) suggests some investors are cautious despite bullish research.

12 Analyst Rating

Wall Street analysts forecast IMAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMAX is 44 USD with a low forecast of 34 USD and a high forecast of 47 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

11 Buy

1 Hold

0 Sell

Strong Buy

Current: 36.410

Low

Averages

High

Current: 36.410

Low

Averages

High

Wells Fargo

Overweight

maintain

$40 -> $47

AI Analysis

2025-12-18

Reason

Wells Fargo

Price Target

$40 -> $47

AI Analysis

2025-12-18

maintain

Overweight

Reason

Wells Fargo raised the firm's price target on Imax to $47 from $40 and keeps an Overweight rating on the shares. The firm views Imax as uniquely levered to structural shifts toward premium, event-driven cinema, and local language hit-making. Recent results already show the accelerating trends driven by its diversified business model. With a strong multi-year slate, improved visibility, and clear 3-year financial targets showcasing the operating leverage in the model with an expanding total addressable market, Imax is one of Wells' favorite stocks within its coverage heading into 2026.

JPMorgan

Neutral -> Overweight

upgrade

$32 -> $47

2025-12-15

Reason

JPMorgan

Price Target

$32 -> $47

2025-12-15

upgrade

Neutral -> Overweight

Reason

JPMorgan upgraded Imax to Overweight from Neutral with a price target of $47, up from $32. The company's momentum can accelerate on a "strong slate" of movies that includes Avatar: Fire and Ash, The Odyssey, and Narnia, the analyst tells investors in a research note. JPMorgan views Imax as a live experience platform and premium consumer brand, "worthy of a greater valuation."

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IMAX

Unlock Now

IMAX Should I Buy

IMAX Should I Buy

Should You Buy Imax Corp (IMAX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch